Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
04/2004
04/29/2004WO2004018472A3 Pyrimido compounds having antiproliferative activity
04/29/2004WO2004014311A3 Nogo receptor antagonists
04/29/2004WO2004012732A3 Use of a proteasome inhibitor in the treatment of endothelial dysfunction and/or in a low-dose proteasome inhibitor therapy
04/29/2004WO2004011402A3 Novel arylimidazole derivatives, preparation and therapeutic uses thereof
04/29/2004WO2004000230A3 Cyclothiocarbamative derivatives as pr modulators and use thereof for treatment of skin disorders
04/29/2004WO2003101996A8 Esters in position 20 of camptothecins
04/29/2004WO2003099823A3 1,3-diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
04/29/2004WO2003097649A3 1-oxa-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof
04/29/2004WO2003093242A3 Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade
04/29/2004WO2003087368A3 Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification
04/29/2004WO2003087367A3 Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye
04/29/2004WO2003075840A3 Human antibodies specific to kdr and uses thereof
04/29/2004WO2003057912A3 Molecular trichogram
04/29/2004WO2003042399A9 A nucleic acid encoding a g-protein-coupled receptor, and uses thereof
04/29/2004WO2003020949A3 Targeted nucleic acid constructs and uses related thereto
04/29/2004WO2003015612A9 Materials and methods to promote repair of nerve tissue
04/29/2004WO2003013537A9 Irinotecan for treatment of cancer
04/29/2004WO2003013536A9 Methods for treatment of cancer using irinotecan based on ugt1a1
04/29/2004WO2003013535A9 Use of irinotecan for improved treatment of cancer based on mdr1
04/29/2004WO2003013534A9 Methods for the treatment of cancer with irinotecan based on cyp3a5
04/29/2004WO2003013533A9 Methods for improved treatment of cancer with irinotecan based on mrp1
04/29/2004WO2003010196A3 Variants and exons of the glyt1 transporter
04/29/2004WO2003009807A3 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods
04/29/2004WO2003003972A3 Kinetic resolution of a intermediate useful in the production of benazepril and analogues thereof
04/29/2004WO2003003004A3 Method for identifying compounds the specifically deplete mast cells
04/29/2004WO2002102787A3 Novel sulfonic acid derivatives
04/29/2004WO2002102391A3 Composition comprising nanoparticulate spironolactone
04/29/2004WO2002070669A3 Secreted proteins
04/29/2004WO2002066056A8 Synthetic vaccines comprising polyhydroxypolymer carriers
04/29/2004WO2002018341A8 Quinoline- (c=o) - (di-, tri- and tetrapeptide) derivatives as caspase inhibitors
04/29/2004WO2001095899A8 Pharmaceutical compositions comprising cannabidiol derivatives
04/29/2004US20040083447 1-Phenyl-4-benzylpiperazines dopamine receptor subtype specific ligands
04/29/2004US20040082807 Novel salt forms of poorly soluble probucol esters and ethers
04/29/2004US20040082805 Cytokine antagonist; immunology, viricides, antitumor agents, anticancer agents
04/29/2004US20040082790 Piperidine amides as modulators of chemokine receptor activity
04/29/2004US20040082789 Thieno[2,3-c]iosquinolines for use as inhibitors of parp
04/29/2004US20040082787 Chemical compounds
04/29/2004US20040082781 Bicyclic nitrogenous fused-ring compound
04/29/2004US20040082763 Diagnosis, therapy of Alzheimer's disease; synthetic antibody
04/29/2004US20040082758 Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
04/29/2004US20040082757 Echinocandin derivatives, pharmaceutical compositions containing same and use thereof as drugs
04/29/2004US20040082666 Antiserotonine agents
04/29/2004US20040082664 Derivatives of hydroxyphenyl, a method for preparing thereof and their pharmaceutical composition
04/29/2004US20040082663 Imidazoline receptor binding compounds
04/29/2004US20040082656 Higher unsaturated fatty acid composition
04/29/2004US20040082653 Using prostaglandin antagonist
04/29/2004US20040082647 Anticholesterol agents; controlling bile acid transfer into intestines
04/29/2004US20040082643 Method for the use of pyranoindole derivatives to treat infection with Hepatitis C virus
04/29/2004US20040082642 Novel estrogen receptor ligands and method III
04/29/2004US20040082640 Use of cox-2 inhibitors for preventing immunodeficiency
04/29/2004US20040082638 Compounds, compositions and methods
04/29/2004US20040082635 Fused cyclic compounds and medicinal use thereof
04/29/2004US20040082631 Pyrazole compositions useful as inhibitors of ERK
04/29/2004US20040082630 1g(a)-Amino-n-hydroxy-acetamide derivatives
04/29/2004US20040082619 Pyridone derivatives having affinity for cannabinoid 2-type receptor
04/29/2004US20040082617 Sulphones which modulate the action of gamma secretase
04/29/2004US20040082605 Use
04/29/2004US20040082603 2,3-Dihydro-isoindol-1-one derivatives
04/29/2004US20040082602 Kinase inhibitor; analgesics; antiarthritic agents; antihistamines; gastrointestinal disorders
04/29/2004US20040082597 Use of CRF antagonists and related compositions
04/29/2004US20040082592 Metabotropic glutamate receptor antagonists
04/29/2004US20040082590 Dietetics; antidiabetic agents; sexual disorders
04/29/2004US20040082589 Quinoline derivatives as nk-3 and nk-2 antagonists
04/29/2004US20040082584 Antiinflammatory agents; antihistamines; skin disorders; antiarthritic agents; antidiabetic agents; autoimmune disease
04/29/2004US20040082583 Chemical compounds
04/29/2004US20040082582 Pyrrolo-triazine aniline compounds useful as kinase inhibitors
04/29/2004US20040082576 Cardiovascular disorders; anticancer agents; antidiabetic agents; dietetics
04/29/2004US20040082575 Compounds and methods for modulation of estrogen receptors
04/29/2004US20040082569 Novel substituted amides, their preparation and use
04/29/2004US20040082567 Antiproliferative agents; anticancer agents; fungicides; antiinflammatory agents
04/29/2004US20040082566 Pyrrolidine sulfonamides
04/29/2004US20040082564 Methods for treating metabolic diseases using malonyl-coa decarboxylase inhibitors
04/29/2004US20040082563 Thrombosis therapy; antitumor agents; anticoagulants; Factor x inhibitors; anticholesterol agents; cardiovascular disorders; antiinflammatory agents
04/29/2004US20040082562 Novel inhibitors of IMPDH enzyme
04/29/2004US20040082556 Inhibitors of type 5 and type 3 17beta-hydroxysteroid dehydrogenase and methods for their use
04/29/2004US20040082555 Use of gaba, inverse agonists in combination with nicotine receptor partial agonist, estrogen, selective estrogen modulators, or vitamin E for the treatment of cognitive disorders
04/29/2004US20040082551 Novel pyrazoles and their use as p38 kinase inhibitors
04/29/2004US20040082550 Tropolone derivative
04/29/2004US20040082548 Cardiovascular disorders; Alzheimer's disease; anticholesterol agents
04/29/2004US20040082547 Prevent thrombosis; anticholesterol agents; cardiovascular disorders; anticancer agents
04/29/2004US20040082542 Useful as modulators of interaction between receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, beta-amyloid and amphoterin
04/29/2004US20040082540 Use of a mixture of sodium hyaluronate and chondroitin sulfate for the treatment of osteoarthritis
04/29/2004US20040082529 Treating or preventing cancer by administering to subject a vector comprising a heterologous polynucleotide operably linked to one or more regulatory sequences derived from an H19, IGF-1 or IGF-2 P4 transcriptional regulatory sequence
04/29/2004US20040082517 Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof
04/29/2004US20040082516 For in vitro/vivo drugs; neuropathy
04/29/2004US20040082512 Drugs for treatment of inflammation/blood brain barrier degradation
04/29/2004US20040082510 Pyk2 phosphorylation by her3 induces tumor invasion
04/29/2004US20040082504 Intratumorally administered lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
04/29/2004US20040082497 For treatment of growth hormone deficiency/polycystic ovary syndrome autoimmune/inflammatory disease
04/29/2004US20040082065 Cascading priming cells; stimulating lymphocytes; incubation
04/29/2004US20040082039 Immunoglobulin fusion proteins
04/29/2004US20040082037 Antiproliferative agents of vascular smooth muscles
04/29/2004US20040082014 Method and test system for identifying substances which protect nerve cells
04/29/2004US20040082009 Compositions and methods for regulating receptor clustering
04/29/2004US20040081984 Ocular tear growth factor-like protein
04/29/2004US20040081971 Gastrointestinal disorders; cardiovascular disorders; autoimmune diseases; cell proliferation; antiinflammatory agents
04/29/2004US20040081714 Cosmetic and/or pharmaceutical preparations
04/29/2004US20040081673 Compositions and methods for the treatment of skin damage
04/29/2004US20040081670 Method for producing an active ingredient concentrate, and an active ingredient concentrate
04/29/2004US20040081665 Chlorella preparations exhibiting immunomodulating properties